Among 6 analysts covering Garrison Capital (NASDAQ:GARS), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Garrison Capital had 15 analyst reports since August 5, 2015 according to SRatingsIntel. As per Thursday, March 17, the company rating was maintained by Stephens. Maxim Group maintained the stock with “Buy” rating in Thursday, August 10 report. On Thursday, November 9 the stock rating was maintained by Robert W. Baird with “Hold”. The stock of Garrison Capital Inc. (NASDAQ:GARS) earned “Buy” rating by Maxim Group on Thursday, November 9. The stock has “Buy” rating by National Securities on Wednesday, August 5. The firm has “Neutral” rating given on Friday, November 6 by Ladenburg Thalmann. Zacks upgraded the stock to “Hold” rating in Tuesday, August 11 report. The rating was maintained by Oppenheimer with “Hold” on Thursday, August 10. Maxim Group maintained it with “Buy” rating and $15 target in Monday, November 9 report. The firm earned “Buy” rating on Wednesday, August 5 by Zacks. See Garrison Capital Inc. (NASDAQ:GARS) latest ratings:
09/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $9.0 Maintain
09/11/2017 Broker: Maxim Group Rating: Buy New Target: $11.0 Maintain
10/08/2017 Broker: Oppenheimer Rating: Hold Maintain
10/08/2017 Broker: Maxim Group Rating: Buy New Target: $11.0000 Maintain
OvaScience, Inc. (OVAS) formed triangle with $1.34 target or 7.00% below today’s $1.44 share price. OvaScience, Inc. (OVAS) has $51.42 million valuation. The stock increased 0.70% or $0.01 during the last trading session, reaching $1.44. About 490,685 shares traded or 8.40% up from the average. OvaScience, Inc. (NASDAQ:OVAS) has declined 82.79% since December 28, 2016 and is downtrending. It has underperformed by 99.49% the S&P500.
Investors sentiment increased to 0.85 in 2017 Q3. Its up 0.19, from 0.66 in 2017Q2. It is positive, as 12 investors sold OvaScience, Inc. shares while 14 reduced holdings. 5 funds opened positions while 17 raised stakes. 19.65 million shares or 2.14% less from 20.08 million shares in 2017Q2 were reported. Bbt Capital Mngmt Limited Liability Corp, Texas-based fund reported 253,680 shares. Fmr Ltd Limited Liability Company accumulated 3.97 million shares. 33,536 were reported by Comml Bank Of Mellon. Retail Bank Of America Corp De reported 1,065 shares or 0% of all its holdings. Trust Communication Of Vermont holds 1,465 shares or 0% of its portfolio. Third Security Ltd Llc stated it has 0.03% in OvaScience, Inc. (NASDAQ:OVAS). Broadfin Cap Limited Liability holds 0.12% or 550,000 shares in its portfolio. Jennison Assoc Ltd Co stated it has 0% of its portfolio in OvaScience, Inc. (NASDAQ:OVAS). National Bank & Trust Of Montreal Can, a Ontario – Canada-based fund reported 908 shares. California Public Employees Retirement Systems holds 26,800 shares. Element Management Ltd Liability has invested 0.01% in OvaScience, Inc. (NASDAQ:OVAS). Citadel Advsrs Ltd Liability has invested 0% in OvaScience, Inc. (NASDAQ:OVAS). Gmt Corp has 801,345 shares. The Massachusetts-based Panagora Asset Inc has invested 0% in OvaScience, Inc. (NASDAQ:OVAS). D E Shaw & Communications has invested 0% in OvaScience, Inc. (NASDAQ:OVAS).
Among 6 analysts covering OvaScience (NASDAQ:OVAS), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. OvaScience had 12 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Outperform” on Friday, August 14. The firm has “Mkt Perform” rating given on Tuesday, September 29 by JMP Securities. Credit Suisse initiated the shares of OVAS in report on Thursday, January 21 with “Underperform” rating. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 4. The firm has “Hold” rating given on Thursday, June 22 by Oppenheimer. The firm earned “Outperform” rating on Wednesday, September 30 by Oppenheimer. On Wednesday, October 21 the stock rating was maintained by Oppenheimer with “Outperform”. Oppenheimer downgraded OvaScience, Inc. (NASDAQ:OVAS) on Monday, January 25 to “Perform” rating. The company was downgraded on Monday, November 9 by Leerink Swann. Wedbush maintained OvaScience, Inc. (NASDAQ:OVAS) rating on Tuesday, August 11. Wedbush has “Outperform” rating and $46 target.
Analysts await OvaScience, Inc. (NASDAQ:OVAS) to report earnings on March, 1. They expect $-0.29 EPS, up 54.69% or $0.35 from last year’s $-0.64 per share. After $-0.25 actual EPS reported by OvaScience, Inc. for the previous quarter, Wall Street now forecasts 16.00% negative EPS growth.